细胞转染市场规模、份额和成长分析：按转染方法、最终用户和地区划分－2026-2033年产业预测

2024年全球细胞转染市场价值为24亿美元，预计将从2025年的26.2亿美元成长到2033年的53.4亿美元。预测期（2026-2033年）的复合年增长率预计为9.3%。

包括学术界、工业界和临床应用在内的各个领域对创新基因修饰工具的需求日益增长，推动了全球细胞转染市场的发展。高效的核酸递送对于功能基因组学以及细胞和基因疗法的开发等领域的进步至关重要。随着效率和扩充性变得至关重要，非病毒化学试剂正显着转向优化的电穿孔系统和病毒载体。此外，CAR-T疗法等细胞和基因疗法的日益普及也对可靠的转染方法提出了更高的要求，迫使供应商持续提升其产品竞争力。人工智慧正在透过优化设计和工作流程，打造伙伴关係解决方案，从而改变这一领域。这些解决方案能够提高可重复性，缩短开发週期，并促进生物製药和生物技术生态系统内的合作。

全球细胞转染市场驱动因素

基因疗法和核酸药物研究的不断深入，显着提升了对高效细胞转染解决方案的需求。研究人员在药物发现和临床前开发过程中，需要可靠的方法将遗传物质导入各种细胞类型。这种科研趋势促使实验室和受託研究机构投资于检验的转染试剂和平台，以简化复杂的工作流程。为此，供应商正致力于拓展产品线并提升产品效能。因此，持续的研究活动推动了转染领域的创新和商业化，从而增强了供应链，并提升了市场竞争力。

全球细胞转染市场的限制因素

全球细胞转染市场面临许多限制因素，其中高品质转染试剂、专用递送系统和自动化平台成本高成本且波动较大。这些经济壁垒尤其影响学术实验室和小规模服务供应商，阻碍了他们采购必要材料的能力，并限制了市场渗透率。预算限制往往迫使研究人员选择成熟的方法而非新兴且昂贵的创新技术，从而抑制了对尖端产品的需求。此外，对成本的高度敏感性限制了常规应用所需的方法检验和最佳化投资，最终导致商业性化应用受限，并阻碍了供应商拓展产品线和探索细分市场机会。

全球细胞转染市场趋势

全球细胞转染市场呈现显着上升趋势，这主要得益于单细胞应用中对精准、低毒性递送方法日益增长的需求。研究人员正致力于开发先进的转染技术，以促进下游体学工作流程所需的稳定表达，同时保持细胞活力。这一趋势推动了扩充性、微创且与微流体平台相容的技术的发展，并促进了这些技术与单细胞定序和高内涵分析的融合。随着供应商将可重复性和易整合性置于优先地位，细胞转染正逐渐成为支持药物发现、生物标记鑑定、治疗方法开发和临床应用等各个领域的关键基础技术。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球细胞转染市场规模：依转染方法及复合年增长率划分（2026-2033 年）

• 电穿孔
• 脂质体
• 磷酸钙法
• 病毒转染
• 其他的

全球细胞转染市场规模：依最终用户和复合年增长率划分（2026-2033 年）

• 学术机构
• 製药公司
• 生技公司
• CRO（受託研究机构）

全球细胞转染市场规模及复合年增长率（2026-2033）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• Thermo Fisher Scientific, Inc.
• QIAGEN
• Lonza
• Promega Corporation
• Bio-Rad Laboratories Inc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• OriGene Technologies Inc.
• MaxCyte, Inc.
• POLYPLUS TRANSFECTION
• Agilent Technologies, Inc.
• Takara Bio Inc.
• GenScript Biotech Corporation
• ATCC
• Cellink
• EMD Millipore
• SignaGen Laboratories
• Mirus Bio LLC
• New England Biolabs, Inc.
• Cellecta, Inc.

结论与建议

Global Cell Transfection Market size was valued at USD 2.4 Billion in 2024 and is poised to grow from USD 2.62 Billion in 2025 to USD 5.34 Billion by 2033, growing at a CAGR of 9.3% during the forecast period (2026-2033).

The global cell transfection market is driven by an increasing demand for innovative gene-modification tools in various sectors, including academia, industry, and clinical applications. Efficient nucleic acid delivery is crucial for advancements in areas such as functional genomics and the development of cell and gene therapies. There has been a notable transition from non-viral chemical reagents to optimized electroporation systems and viral vectors, as efficiency and scalability become paramount. Additionally, a growing prevalence of cell and gene therapies, like CAR-T, heightens the need for robust transfection methods, prompting suppliers to enhance their offerings. AI is transforming this landscape by optimizing design and workflows, creating integrated solutions that enhance reproducibility, decrease development time, and stimulate partnerships in biopharma and biotechnology ecosystems.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Transfection market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell Transfection Market Segments Analysis

Global cell transfection market is segmented by transfection methods, end users and region. Based on transfection methods, the market is segmented into Electroporation, Lipofection, Calcium Phosphate, Viral Transfection and Others. Based on end users, the market is segmented into Academic Institutes, Pharmaceutical Companies, Biotechnology Companies and Contract Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cell Transfection Market

The growth in research dedicated to gene therapies and nucleic acid-based medicines has significantly fueled the demand for effective cell transfection solutions. Researchers require dependable methods to deliver genetic material into various cell types for their discovery and preclinical development efforts. This scientific emphasis drives laboratories and contract research organizations to invest in validated transfection reagents and platforms that facilitate complex workflows. In response, suppliers are expanding their product offerings and enhancing performance characteristics. As a result, ongoing research endeavors stimulate innovation and commercialization within the transfection sector, strengthening supply chains and improving competitive options in the market.

Restraints in the Global Cell Transfection Market

The Global Cell Transfection market faces significant constraints due to high and variable costs associated with premium transfection reagents, specialized delivery systems, and automation platforms. These financial barriers particularly impact academic laboratories and smaller service providers, hindering their ability to procure necessary materials and limiting market penetration. Budget constraints often force researchers to favor established techniques over newer, pricier innovations, which can stifle demand for cutting-edge products. Additionally, cost sensitivity restricts necessary investment in the validation and optimization of methods needed for routine application, ultimately diminishing commercial adoption and discouraging suppliers from expanding their product ranges or exploring niche opportunities.

Market Trends of the Global Cell Transfection Market

The global cell transfection market is experiencing a significant upward trajectory driven by the increasing demand for precise and low-toxicity delivery methods in single cell applications. Researchers are focusing on advanced transfection techniques that maintain cell viability while facilitating robust expression essential for downstream omics workflows. This trend is prompting the development of scalable and gentle technologies compatible with microfluidic platforms, enhancing integration with single cell sequencing and high content analysis. As vendors prioritize reproducibility and ease of integration, cell transfection is emerging as a critical enabler for discovery, biomarker identification, therapeutic development, and clinical applications across various sectors.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cell Transfection Market Size by Transfection Methods & CAGR (2026-2033)

• Market Overview
• Electroporation
• Lipofection
• Calcium Phosphate
• Viral Transfection
• Others

Global Cell Transfection Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Academic Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

Global Cell Transfection Market Size & CAGR (2026-2033)

• North America (Transfection Methods, End Users)
  • US
  • Canada
• Europe (Transfection Methods, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Transfection Methods, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Transfection Methods, End Users)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Transfection Methods, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OriGene Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MaxCyte, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• POLYPLUS TRANSFECTION
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ATCC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellink
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Millipore
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SignaGen Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mirus Bio LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellecta, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations